Texas is currently home to 5025 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
Recruiting
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of balcinrenone in patients with mild and moderate hepatic impairment in comparison to a matched healthy control group.
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
05/08/2024
Locations: Research Site, San Antonio, Texas
Conditions: Hepatic Impairment
A Study of Pitolisant in Patients With Prader-Willi Syndrome
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other... Read More
Gender:
All
Ages:
6 years and above
Trial Updated:
05/08/2024
Locations: Texas Valley Clinical Research, Weslaco, Texas
Conditions: Prader-Willi Syndrome
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Recruiting
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Gender:
All
Ages:
Between 60 years and 100 years
Trial Updated:
05/08/2024
Locations: Clinical Trials of Texas, LLC DBA Flourish Research, San Antonio, Texas
Conditions: Muscle Loss, Obesity
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
Recruiting
The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: Research Site, Houston, Texas
Conditions: Gastric Cancer, Gastroesophageal Junction Cancer, Pancreatic Adenocarcinoma
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Recruiting
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of participants diagnosed with moderate to severe atopic dermatitis (AD), whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for SC injection compared with placebo in participant... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
05/08/2024
Locations: Center for Clinical Studies, LTD. LLP Site Number : 8401063, Houston, Texas
Conditions: Dermatitis Atopic
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
Recruiting
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the part... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
05/08/2024
Locations: Sarah Cannon Research Institute Site Number : 8400002, Austin, Texas
Conditions: Chronic Graft Versus Host Disease
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
05/08/2024
Locations: Texas Institute for Neuroogical Disorders-Sherman Site Number : 8400018, Sherman, Texas
Conditions: Multiple Sclerosis
A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Recruiting
The primary objectives of this study are to: Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors Determine the recommended phase 2 dose and the maximum tolerated dose for AMG 355 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/08/2024
Locations: South Texas Accelerated Research Therapeutics, San Antonio, Texas
Conditions: Advanced Solid Tumors
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Recruiting
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-expres... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/08/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
All
Ages:
Between 40 years and 90 years
Trial Updated:
05/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure
Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Recruiting
This is a parallel, Phase 2, 2-arm, double-blind, randomized, multicenter, multinational, placebo-controlled study to evaluate efficacy, safety, pharmacokinetics (PK), and biological effects of treatment of subcutaneous injection of amlitelimab compared with placebo in male and female participants aged 18 to 70 years with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to measure standardized clinician reported and participant-reported outcomes (ClinRO and PRO), s... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
05/08/2024
Locations: Center for Clinical Studies, LTD. LLP Site Number : 8400001, Houston, Texas
Conditions: Hidradenitis
Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma
Recruiting
This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig in adult participants aged 18 to 80 years, (inclusive) with moderate-to-severe asthma.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/08/2024
Locations: Orion Clinical Research Site Number : 8400001, Austin, Texas
Conditions: Asthma